{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:28:29Z","timestamp":1793845709355,"version":"4.6.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.mayocp.2026.01.010","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:48:38Z","timestamp":1776800918000},"page":"1347-1366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Acute Estimated Glomerular Filtration Rate Decline After Initiation of Therapies That Slow Kidney Disease Progression: Clinical Practice Implications"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-0429","authenticated-orcid":false,"given":"David Z.I.","family":"Cherney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radica Z.","family":"Alicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4S","key":"10.1016\/j.mayocp.2026.01.010_bib1","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.010_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000534071","article-title":"Disease burden and epidemiological trends of chronic kidney disease at the global, regional, national levels from 1990 to 2019","volume":"148","author":"Ying","year":"2024","journal-title":"Nephron"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.010_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic kidney disease and the global public health agenda: an international consensus","volume":"20","author":"Francis","year":"2024","journal-title":"Nat Rev Nephrol"},{"issue":"18","key":"10.1016\/j.mayocp.2026.01.010_bib4","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.mayocp.2026.01.010_bib6","first-page":"13","article-title":"The interplay between diabetes, cardiovascular disease, and kidney disease","volume":"1","author":"Usman","year":"2021"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.010_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jamacardio.2017.4228","article-title":"Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk: observations from the SAVOR-TIMI 53 trial","volume":"3","author":"Scirica","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"24","key":"10.1016\/j.mayocp.2026.01.010_bib8","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.010_bib9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.mayocp.2026.01.010_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12933-015-0204-5","article-title":"Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors","volume":"14","author":"Cea Soriano","year":"2015","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.010_bib11","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.kint.2016.07.013","article-title":"Infection in advanced chronic kidney disease leads to increased risk of cardiovascular events, end-stage kidney disease and mortality","volume":"90","author":"Cheikh Hassan","year":"2016","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.010_bib12","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2215\/CJN.03940321","article-title":"Association of polypharmacy with kidney disease progression in adults with CKD","volume":"16","author":"Kimura","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.mayocp.2026.01.010_bib13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.ajkd.2023.09.003","article-title":"KDOQI commentary on the KDIGO 2022 update to the Clinical Practice Guideline for Diabetes Management in CKD","volume":"83","author":"Mottl","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.mayocp.2026.01.010_bib14","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.010_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.010_bib16","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.010_bib17","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.010_bib18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.010_bib19","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.mayocp.2026.01.010_bib20","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.mayocp.2026.01.010_bib21","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.010_bib22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.010_bib23","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.ekir.2024.04.028","article-title":"Effects of once-weekly semaglutide on kidney disease outcomes by KDIGO risk category in the SUSTAIN 6 trial","volume":"9","author":"Tuttle","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.010_bib24","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.mayocp.2026.01.010_bib25","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1681\/ASN.2019010008","article-title":"Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data","volume":"30","author":"Grams","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.010_bib26","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.010_bib27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial","volume":"12","author":"Staplin","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.mayocp.2026.01.010_bib28","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"16","key":"10.1016\/j.mayocp.2026.01.010_bib29","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.mayocp.2026.01.010_bib30","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.010_bib31","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.mayocp.2026.01.010_bib32","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.mayocp.2026.01.010_bib33","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2026.01.010_bib34","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.010_bib35","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ndt\/gfac157","article-title":"Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study","volume":"38","author":"Ruilope","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1016\/j.mayocp.2026.01.010_bib36","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2215\/CJN.01130121","article-title":"Ertugliflozin and slope of chronic eGFR: prespecified analyses from the randomized VERTIS CV trial","volume":"16","author":"Cherney","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.010_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.010_bib38","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1093\/ndt\/gfr696","article-title":"Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the irbesartan diabetic nephropathy trial","volume":"27","author":"Evans","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.mayocp.2026.01.010_bib39","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.010_bib40","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.010_bib41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41572-024-00589-9","article-title":"Chronic kidney disease","volume":"11","author":"Romagnani","year":"2025","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.010_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dbi16-0056","article-title":"Back to the future: glomerular hyperfiltration and the diabetic kidney","volume":"66","author":"Tuttle","year":"2017","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.mayocp.2026.01.010_bib43","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/j.2040-4603.2011.tb00365.x","article-title":"Pathophysiology of the diabetic kidney","volume":"1","author":"Vallon","year":"2011","journal-title":"Compr Physiol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.010_bib44","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00125-009-1268-0","article-title":"Is hyperfiltration associated with the future risk of developing diabetic nephropathy? a meta-analysis","volume":"52","author":"Magee","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.mayocp.2026.01.010_bib45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2369-11-3","article-title":"Large kidneys predict poor renal outcome in subjects with diabetes and chronic kidney disease","volume":"11","author":"Rigalleau","year":"2010","journal-title":"BMC Nephrol"},{"issue":"10","key":"10.1016\/j.mayocp.2026.01.010_bib46","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.2337\/dc11-2189","article-title":"Glomerular hyperfiltration and renal disease progression in type 2 diabetes","volume":"35","author":"Ruggenenti","year":"2012","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.010_bib47","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.3390\/ijms23073915","article-title":"A shared nephroprotective mechanism for renin-angiotensin-system inhibitors, sodium-glucose co-transporter 2 inhibitors, and vasopressin receptor antagonists: immunology meets hemodynamics","volume":"23","author":"Capolongo","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.010_bib48","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-022-00559-y","article-title":"Glomerular hyperfiltration","volume":"18","author":"Cortinovis","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.010_bib49","first-page":"F85","article-title":"Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation","volume":"241","author":"Hostetter","year":"1981","journal-title":"Am J Physiol"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.010_bib50","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/s41440-019-0320-9","article-title":"Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect?","volume":"42","author":"Sato","year":"2019","journal-title":"Hypertens Res"},{"key":"10.1016\/j.mayocp.2026.01.010_bib51","series-title":"StatPearls","article-title":"Sodium-glucose transport protein 2 (SGLT2) inhibitors","author":"Padda","year":"2025"},{"key":"10.1016\/j.mayocp.2026.01.010_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1125693","article-title":"Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus","volume":"14","author":"Lv","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.010_bib53","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"issue":"34","key":"10.1016\/j.mayocp.2026.01.010_bib54","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1093\/eurheartj\/ehaf316","article-title":"Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial","volume":"46","author":"Berger","year":"2025","journal-title":"Eur Heart J"},{"issue":"suppl A):(12","key":"10.1016\/j.mayocp.2026.01.010_bib55","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0735-1097(25)00908-8","article-title":"Mechanisms of cardiovascular benefit with finerenone: a causal mediation analysis of the joint effects of systolic blood pressure and albuminuria reduction","volume":"85","author":"Agarwal","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.mayocp.2026.01.010_bib56","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.010_bib57","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1159\/000524889","article-title":"Initial eGFR changes with ertugliflozin and associations with clinical parameters: analyses from the VERTIS CV trial","volume":"53","author":"Cherney","year":"2022","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.1016\/j.mayocp.2026.01.010_bib58","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.010_bib59","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","article-title":"Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF","volume":"146","author":"Adamson","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.010_bib60","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.010_bib61","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","article-title":"Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice","volume":"99","author":"Oshima","year":"2021","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.mayocp.2026.01.010_bib62","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1681\/ASN.2022030306","article-title":"Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD","volume":"33","author":"Jongs","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.mayocp.2026.01.010_bib63","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.010_bib64","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.010_bib65","first-page":"1816","article-title":"Biology and clinical use of glucagon-like peptide-1 receptor agonists in vascular protection","volume":"39","author":"Yau","year":"2023","journal-title":"Can J Cardiol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.010_bib66","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MNH.0000000000000894","article-title":"Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease","volume":"32","author":"Alicic","year":"2023","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.010_bib67","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"1-2","key":"10.1016\/j.mayocp.2026.01.010_bib68","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000529374","article-title":"Indicators of kidney fibrosis in patients with type 2 diabetes and chronic kidney disease treated with dulaglutide","volume":"54","author":"Tuttle","year":"2023","journal-title":"Am J Nephrol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.01.010_bib69","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.medj.2021.10.004","article-title":"Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors","volume":"2","author":"Cherney","year":"2021","journal-title":"Med"},{"issue":"7","key":"10.1016\/j.mayocp.2026.01.010_bib70","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/ndt\/gfae024","article-title":"How to assess kidney outcomes in obese people with substantial weight loss: the case of GLP1- and dual-receptor agonists","volume":"39","author":"Rothberg","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1016\/j.mayocp.2026.01.010_bib71","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.010_bib72","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.010_bib73","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"issue":"82","key":"10.1016\/j.mayocp.2026.01.010_bib74","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1046\/j.1523-1755.62.s82.13.x","article-title":"Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL study","volume":"62","author":"Shahinfar","year":"2002","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"10.1016\/j.mayocp.2026.01.010_bib75","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.010_bib76","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2026.01.010_bib77","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.2337\/dc22-0382","article-title":"Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial","volume":"45","author":"Mosenzon","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.010_bib78","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.mayocp.2026.01.010_bib79","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/ejhf.2578","article-title":"Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced","volume":"24","author":"Zannad","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.010_bib80","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ejhf.3136","article-title":"Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved","volume":"26","author":"Rastogi","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"10.1016\/j.mayocp.2026.01.010_bib81","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.010_bib82","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamacardio.2023.4664","article-title":"Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial","volume":"9","author":"Mc Causland","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"12","key":"10.1016\/j.mayocp.2026.01.010_bib83","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2026.01.010_bib84","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.kint.2025.03.018","article-title":"Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis","volume":"108","author":"Navaneethan","year":"2025","journal-title":"Kidney Int"},{"issue":"16","key":"10.1016\/j.mayocp.2026.01.010_bib85","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.mayocp.2026.01.010_bib86","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.010_bib87","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.kint.2024.05.024","article-title":"A meta-analysis of randomized controlled clinical trials for implications of acute treatment effects on glomerular filtration rate for long-term kidney protection","volume":"106","author":"Heerspink","year":"2024","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.010_bib88","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1161\/CIRCHEARTFAILURE.111.963256","article-title":"Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction","volume":"4","author":"Testani","year":"2011","journal-title":"Circ Heart Fail"},{"issue":"5","key":"10.1016\/j.mayocp.2026.01.010_bib89","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.kint.2019.05.019","article-title":"Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction","volume":"96","author":"McCallum","year":"2019","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.010_bib90","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2024.11.020","article-title":"Initial decline in glomerular filtration rate with finerenone in HFmrEF\/HFpEF: a prespecified analysis of FINEARTS-HF","volume":"85","author":"Matsumoto","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.mayocp.2026.01.010_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110908","article-title":"Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial","volume":"204","author":"Heerspink","year":"2023","journal-title":"Diabet Res Clin Pract"},{"issue":"2","key":"10.1016\/j.mayocp.2026.01.010_bib92","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/ndt\/gfae132","article-title":"Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial","volume":"40","author":"Heerspink","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.mayocp.2026.01.010_bib93","doi-asserted-by":"crossref","first-page":"750","DOI":"10.4103\/0366-6999.152483","article-title":"Decrease of glomerular filtration rate may be attributed to the microcirculation damage in renal artery stenosis","volume":"128","author":"Dong","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.mayocp.2026.01.010_bib94","series-title":"StatPearls","article-title":"Physiology, renal blood flow and filtration","author":"Dalal","year":"2025"},{"issue":"4","key":"10.1016\/j.mayocp.2026.01.010_bib95","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1053\/j.ajkd.2020.03.023","article-title":"NSAIDs in CKD: are they safe?","volume":"76","author":"Baker","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"16","key":"10.1016\/j.mayocp.2026.01.010_bib96","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/CIRCULATIONAHA.123.068524","article-title":"Accelerated risk-based implementation of guideline-directed medical therapy for type 2 diabetes and chronic kidney disease","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.mayocp.2026.01.010_bib97","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.2337\/dc25-1673","article-title":"Impact of baseline GLP-1 receptor agonist use on albuminuria reduction and safety with simultaneous initiation of finerenone and empagliflozin in type 2 diabetes and chronic kidney disease (CONFIDENCE trial)","volume":"48","author":"Agarwal","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mayocp.2026.01.010_bib98","unstructured":"Jardiance (empagliflozin). Prescribing information. Boehringer Ingelheim Pharmaceuticals. 2022. Accessed July 29, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/204629s063lbl.pdf"},{"key":"10.1016\/j.mayocp.2026.01.010_bib99","series-title":"Prescribing information","year":"2023"},{"key":"10.1016\/j.mayocp.2026.01.010_bib100","article-title":"Prescribing information","year":"2023","journal-title":"Janssen Pharmaceuticals"},{"key":"10.1016\/j.mayocp.2026.01.010_bib104","series-title":"Prescribing information","year":"2017"},{"key":"10.1016\/j.mayocp.2026.01.010_bib105","series-title":"Prescribing information","year":"2019"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.01.010_bib106","first-page":"S181","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes - 2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mayocp.2026.01.010_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105835","article-title":"Hyperkalemia with RAAS inhibition: mechanism, clinical significance, and management","volume":"172","author":"Hundemer","year":"2021","journal-title":"Pharmacol Res"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561962604334X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561962604334X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:01:38Z","timestamp":1793844098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002561962604334X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":103,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S002561962604334X"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.01.010","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Estimated Glomerular Filtration Rate Decline After Initiation of Therapies That Slow Kidney Disease Progression: Clinical Practice Implications","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}]}}